119 related articles for article (PubMed ID: 18565159)
1. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease.
Pascua M; Su C; Lewis JD; Brensinger C; Lichtenstein GR
Aliment Pharmacol Ther; 2008 Sep; 28(5):545-56. PubMed ID: 18565159
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.
Renna S; Cammà C; Modesto I; Cabibbo G; Scimeca D; Civitavecchia G; Mocciaro F; Orlando A; Enea M; Cottone M
Gastroenterology; 2008 Nov; 135(5):1500-9. PubMed ID: 18823987
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.
Su C; Lichtenstein GR; Krok K; Brensinger CM; Lewis JD
Gastroenterology; 2004 May; 126(5):1257-69. PubMed ID: 15131785
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
5. Interventions for prevention of post-operative recurrence of Crohn's disease.
Doherty G; Bennett G; Patil S; Cheifetz A; Moss AC
Cochrane Database Syst Rev; 2009 Oct; (4):CD006873. PubMed ID: 19821389
[TBL] [Abstract][Full Text] [Related]
6. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.
Ford AC; Luthra P; Hanauer SB; Travis SP; Harris MS; Reinisch W
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):1981-90. PubMed ID: 25218669
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Ullman TA; Ford AC; Abreu MT; Abadir A; Marshall JK; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):661-73. PubMed ID: 21407187
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
10. Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
Sharma T; Ma C; Sedano R; Hanzel J; McDonald C; Hogan M; Kochhar GS; Narula N; Peyrin-Biroulet L; Danese S; MacDonald JK; Jairath V
J Crohns Colitis; 2023 Apr; 17(4):644-658. PubMed ID: 36271904
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.
Vuyyuru SK; Nguyen TM; Hogan M; Raine T; Noor NM; Narula N; Verstockt B; Feagan BG; Singh S; Ma C; Jairath V
Inflamm Bowel Dis; 2024 Apr; 30(4):651-659. PubMed ID: 37002875
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection.
Van Gossum A; Dewit O; Louis E; de Hertogh G; Baert F; Fontaine F; DeVos M; Enslen M; Paintin M; Franchimont D
Inflamm Bowel Dis; 2007 Feb; 13(2):135-42. PubMed ID: 17206696
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.
Ma C; Hussein IM; Al-Abbar YJ; Panaccione R; Fedorak RN; Parker CE; Nguyen TM; Khanna R; Siegel CA; Peyrin-Biroulet L; Pai RK; Vande Casteele N; D'Haens GR; Sandborn WJ; Feagan BG; Jairath V
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1407-1419.e22. PubMed ID: 29596987
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.
Su C; Lewis JD; Goldberg B; Brensinger C; Lichtenstein GR
Gastroenterology; 2007 Feb; 132(2):516-26. PubMed ID: 17258720
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease.
Burr NE; Hall B; Hamlin PJ; Selinger CP; Ford AC; O'Connor A
J Crohns Colitis; 2019 May; 13(6):693-701. PubMed ID: 30561586
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
18. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
Almradi A; Sedano R; Hogan M; Zou GY; MacDonald JK; Parker CE; Hanzel J; Crowley E; Singh S; D'Haens G; Sandborn WJ; Feagan BG; Ma C; Jairath V
J Crohns Colitis; 2022 Jun; 16(5):717-736. PubMed ID: 34758084
[TBL] [Abstract][Full Text] [Related]
20. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials.
Duijvestein M; Jeyarajah J; Guizzetti L; Zou G; Parker CE; van Viegen T; VandeCasteele N; Khanna R; Van Der Aa A; Sandborn WJ; Feagan BG; D'Haens GR; Jairath V
Clin Gastroenterol Hepatol; 2020 May; 18(5):1121-1132.e2. PubMed ID: 31442599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
